Aarti Pharmalabs Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board also approved the change in designation for Shri Rashesh C. Gogri from Non-Executive Director to Managing Director, effective October 1, 2026. Smt. Hetal Gogri Gala will transition from Managing Director to Executive Director. These changes are subject to shareholder approval and signify strategic shifts in leadership.
Financial Performance Highlights
Aarti Pharmalabs Limited convened its Board of Directors meeting on August 7, 2026, where it considered and approved the unaudited financial results for the quarter ended June 30, 2026. The results, both standalone and consolidated, were based on the recommendation of the Audit Committee and included a limited review report.
The company reported a Net Profit of ₹7,130.66 Lakhs for the standalone quarter ended June 30, 2026, compared to ₹6,203.07 Lakhs in the previous quarter. Consolidated Net Profit stood at ₹7,614.27 Lakhs for the same period. Revenue from operations for the standalone entity was ₹53,458.78 Lakhs.
Key Leadership Changes Approved
In a significant management restructuring, the Board approved a change in the designation of Shri Rashesh C. Gogri (DIN: 00066291) from Non-Executive Director to Managing Director. This change is effective from October 1, 2026, and is subject to shareholder approval at the upcoming Annual General Meeting.
Concurrently, Smt. Hetal Gogri Gala (DIN: 00005499) will move from her role as Managing Director to Executive Director of the Company, also effective October 1, 2026, pending shareholder consent.
Capacity Expansion and Committee Reconstitution
The Board also approved an approved capacity addition for Development of Intermediate Block at an estimated capex of Rs.149 Crores. This expansion is aimed at serving intermediate and CDMO customers and will be financed through internal accruals and borrowings.
Furthermore, the reconstitution of the Audit Committee, Corporate Social Responsibility (CSR) Committee, and Stakeholders Relationship Committee was approved, with changes taking effect from October 1, 2026, and immediately for the Stakeholders Relationship Committee, respectively.
The meeting commenced at 02:00 p.m. and concluded at 06:00 p.m. The detailed financial results and disclosures are available on the company’s website.
Source: BSE
